《2023年欧洲器官移植学会共识声明:肝移植中的生物标志物》摘译

An excerpt of European Society for Organ Transplantation consensus statement on biomarkers in liver transplantation(2023)

2023年8月,欧洲器官移植学会在线发表了“2023年欧洲器官移植学会共识声明:肝移植中的生物标志物”。该共识主要围绕肝移植中的生物标志物、临床适用性和未来需求等方面展开,通过回顾有关原发性疾病复发、慢性肾脏疾病发展和安全摆脱免疫抑制的文献,来探索新的生物标志物在预测肝移植预后方面的作用。该共识从肝移植后复发性肝脏疾病、复发性肝细胞癌、摆脱免疫抑制、慢性肾脏疾病进展四个方面展开研究,强调了生物标志物在预测或检测疾病复发中的重要性,同时也提出了仍需要更大规模的前瞻性研究以提高证据质量。笔者团队对该共识声明进行摘译,系统介绍了该共识声明中四个方面的研究以及相关讨论和结论,以期为肝移植中新生物标志物的发现和探索提供更多循证医学证据。

In August 2023,the European Society for Organ Transplantation(ESOT)published the ESOT Consensus Statement on Biomarkers in Liver Transplantation online.The consensus statement focuses on biomarkers in liver transplantation,clinical applicability,and future needs and explores the role of new biomarkers in predicting liver transplantation outcomes by reviewing the literature on primary disease recurrence,development of chronic kidney disease(CKD),and safe weaning of immunosuppression.This consensus statement conducts studies from the four aspects of recurrent liver disease after liver transplantation,recurrent hepatocellular carcinoma,weaning of immunosuppression,and CKD progression,emphasizes the importance of biomarkers in predicting or detecting disease recurrence,and proposes that large-scale prospective studies are still needed to improve the quality of evidence.The author’s team gives an excerpt of the consensus statement and systematically introduces the four aspects of the consensus statement and related discussions and conclusions,in order to provide more evidence-based medical evidence for identifying and exploring new biomarkers for liver transplantation.